Compare Public Storage (PSA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs Regeneron Pharmaceuticals Inc — how do they compare? Public Storage trades at $290.28 (market cap $53.35B), while Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Public Storage pays the higher dividend (4.2%). Which is the better fit depends on your goals — on Pluang, investors hold Public Storage for 130 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PSA | REGN | |
|---|---|---|
Market Cap | $53.35B | $76.14B |
Volume | 1,176,034 | 500,239 |
Sector | Real Estate | Health |
52-Week High | $330.47 | $852.03 |
52-Week Low | $258.44 | $557.73 |
Typical Hold Time | 130 Days | 107 Days |
Enterprise Value | $67.62B | $70.85B |
Dividend Yield | 4.2% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $287.72, up 2.03% today, with a bearish technical signal but strong fundamentals including a 41.8% net income margin and consistent earnings beats. The stock faces resistance near $288, with support at $282. Recent developments include the completion of the Public Storage Canada acquisition and a $400 million senior notes offering in the Canadian market, signaling expansion efforts.
The outlook is mixed: analyst consensus targets $328.33 (14% upside), but technicals and some news highlight valuation concerns. Key risks include interest rate sensitivity and competitive pressures in the REIT sector. Earnings momentum and a 4.05% yield offer support, though investor caution is warranted amid bearish indicators.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
